Latest Breaking News On - Tim clackson - Page 1 : comparemela.com

Months after ending cancer program, Theseus lays off 72%

Months after ending cancer program, Theseus lays off 72%
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesTim clacksonWilliam shakespeareTheseus pharmaceutical

Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024.

United kingdomUnited statesTim clacksonJosh rappaportPrnewswire theseus pharmaceuticals incTheseus pharmaceuticals incExchange commissionDrug administrationTheseus pharmaceuticalsChief executive officerUpcoming expected milestonesInvestigational new drug applicationQuarter financial resultsTheseu formQuarterly reportsConsolidated statements

Theseus Pharmaceuticals Terminates Development of THE-630 in Gastrointestinal Stromal Tumors

Theseus Pharmaceuticals has announced that the development of THE-630 as a potential therapeutic option for patients with gastrointestinal stromal tumor has been terminated, and enrollment to the ongoing phase 1/2 trial evaluating the agent’s safety and efficacy in this population has been discontinued.

Tim clacksonTheseus pharmaceuticalsTheseus pharmaceuticals incGastrointestinal cancer

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST

Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) Company prioritizing THE-349, a.

United statesUnited kingdomTim clacksonJosh rappaportDrug administrationPrnewswire theseus pharmaceuticals incTheseus pharmaceuticals incExchange commissionTheseus pharmaceuticalsChief executive officerInvestigational new drug applicationTheseu formQuarterly reports

Theseus Pharmaceuticals (THRX) to Terminate Development of THE-630 in Patients with GIST

Theseus Pharmaceuticals (THRX) to Terminate Development of THE-630 in Patients with GIST
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJosh rappaportTim clacksonExchange commissionTheseus pharmaceuticals incTheseus pharmaceuticalsPrnewswire theseus pharmaceuticals incDrug administrationChief executive officerInvestigational new drug applicationTheseu formQuarterly reports